Limited guidance exists for dosing melphalan for autologous stem cell transplantation (ASCT) in the obese patient population, because the current literature reports conflicting clinical outcomes between obese and nonobese patients. In 2014, the American Society for Blood and Marrow Transplantation published conditioning chemotherapy dosing guidelines for obese patients and recommended dosing of melphalan using actual body weight (ABW) in the body surface area calculation. The practice at Barnes-Jewish Hospital has consistently been to dose melphalan using adjusted body weight (AdBW), with a 20% correction when a patient weighs ≥120% of his or her ideal body weight (IBW). The purpose of this study was to compare outcomes of melphalan ASCT in patients with multiple myeloma between obese (≥120% IBW) and nonobese (<120% IBW) populations. This retrospective, single-center study included adult patients with multiple myeloma undergoing first ASCT with melphalan conditioning between January 2009 and December 2012. Patient demographic data, transplantation characteristics, and clinical outcomes were collected. The primary outcome was 3-year event-free survival (EFS). Secondary outcomes included response at 100 days post-transplantation, 3-year overall survival, treatment-related mortality (TRM), time to neutrophil engraftment, and hospital length of stay (LOS). To ensure that melphalan dosage adjustment in the obese population did not impact efficacy, the primary outcome was assessed using a noninferiority design, with a predetermined noninferiority margin of 7%. Assuming a 70% 3-year EFS in the nonobese population, a noninferiority margin of 7%, a power of 80%, and an α value of .05, an analysis of 280 patients was required. A total of 270 patients, including 171 (63%) obese patients and 99 (37%) nonobese patients, met our inclusion criteria. Baseline characteristics were well matched between the 2 cohorts, including high-risk cytogenetics, disease severity at diagnosis, and use of maintenance therapy, with the only detectable differences related to weight itself. The 3-year EFS was 41% for the total cohort, with fewer events occurring in the obese cohort compared with the nonobese cohort (51% versus 40%; P = .0025). The 95% lower confidence limit established noninferiority. High-risk cytogenetics, disease severity at diagnosis, and therapy response pre-and post-ASCT were all associated with significantly shorter EFS. No between-group differences in TRM, time to engraftment, or hospital LOS were noted. This retrospective, single-center study found that using AdBW to dose melphalan in obese patients was not inferior to the nonobese population in terms of 3-year EFS. This study adds to the limited evidence on melphalan dosing and suggests that transplantation efficacy is not affected by AdBW dosing in obese patients. Further studies are needed to provide additional insight into the pharmacokinetic differences and best dosing practices for obese patients.
INTRODUCTION
Over the past 40 years, multiple therapies have been approved for the treatment of multiple myeloma with the goal of improving event-free survival (EFS) and overall survival (OS). Despite advancements with novel agents such as bortezomib [1] , carfilzomib [2] , and lenalidomide [3] , high-dose melphalan followed by autologous stem cell transplantation (ASCT) has remained part of standard care in the treatment of patients with multiple myeloma [4] [5] [6] .
In hematopoietic stem cell transplantation, appropriate chemotherapy dosing is critical for efficacy as well as safety [7] . Unfortunately, there is only limited guidance on the dosing of chemotherapeutic agents, specifically high-dose melphalan in the setting of ASCT, for the obese patient population. Given the trend of increasing rates of obesity, this has become a frequent question encountered in practice. In 2014, the American Society for Blood and Marrow Transplantation published guidelines on transplantation conditioning chemotherapy in the obese population and recommended dosing melphalan using actual body weight (ABW) in the body surface area (BSA) calculation, regardless of patient size [7] . Evidence supporting this recommendation is limited and the current literature reports conflicting clinical outcomes when comparing obese and nonobese patients [8] [9] [10] [11] .
At Barnes-Jewish Hospital (BJH), the practice has been to calculate melphalan dosage using adjusted body weight (AdBW) for patients who weigh ≥120% of their ideal body weight (IBW). Given the conflicting evidence on outcomes in obese patients and the unknown effects of dosage adjustment of melphalan, we find this to be an important issue both locally and nationally. The purpose of this study was to compare long-term outcomes of melphalan ASCT in patients with multiple myeloma between obese and nonobese populations to assess the appropriateness of this dosing practice in the obese population. The primary outcome of this study was 3-year event-free survival (EFS). Secondary outcomes included assessment of response at 100 days post-transplantation, 3-year overall survival (OS), treatmentrelated mortality (TRM), time to neutrophil engraftment, and hospital length of stay (LOS).
MATERIALS AND METHODS
This retrospective, single-center, noninferiority study was performed at BJH, a 1315-bed tertiary care academic medical center that is the affiliated teaching hospital for Washington University School of Medicine in St. Louis, MO. The Washington University School of Medicine Human Research Protection Office and the Protocol Review and Monitoring Committee approved this study. An informatics query of OTTR, a Washington University bone marrow transplantation-specific database, was performed to identify patients with multiple myeloma who underwent ASCT between January 1, 2009, and December 31, 2012, and met the study inclusion criteria. The dates selected allowed for complete follow-up of the desired outcomes for all patients. Key inclusion criteria included patient age ≥18 years and a diagnosis of multiple myeloma for which the patient underwent a first ASCT with standard of care high-dose melphalan conditioning at BJH during the study period.
Data Collection
Data was collected from the OTTR query and manual chart review. Two dosing regimens of melphalan, 200 mg/m 2 and 140 mg/m 2 , were included, with the lower dose used in patients age >70 years or receiving hemodialysis. Baseline demographic data collected included age, sex, weight (ABW, IBW, and AdBW), height, body mass index (BMI), dosing BSA, and race. Disease-specific characteristics at the time of diagnosis collected included disease stage and the presence of cytogenetic abnormalities. Information on response before transplantation, previous lines of therapy, and maintenance therapy received after ASCT was also collected. Transplantation characteristics included date of transplantation (day 0), melphalan dose, and CD34 + cells/kg received. Dates of disease progression and death, absolute neutrophil count ≥500 cells/mm 3 , platelet count ≥20,000 cells/mm 3 , response at 100 days post-transplantation, and hospital LOS were also collected.
Definitions
The study cohort was divided into 2 arms, obese and nonobese, to assess outcomes in relation to our dosing practice. The melphalan dosing practice at BJH in the setting of transplantation is summarized in Table 1 , with IBW calculated using Devine's formula, 50 kg + [2.3 kg × (height in inches − 60)] for men and 45.5 kg + [2.3 kg × height in inches − 60)] for women [12] , and AdBW calculated with a 20% correction factor. Based on these dosing practices, in this study the obese cohort comprised was defined as patients who weighed ≥120% of IBW, and the nonobese cohort comprised patients were those who weighed <120% of IBW. High-risk cytogenetics were defined as del(17p), t(14;16), t(14;20), and del(1p), whereas all other cytogenetic abnormalities were considered standard risk [13, 14] . Disease stage at diagnosis was defined by either International Staging System (ISS) score or Durie-Salmon (DS) criteria [15] , depending on available information. EFS was defined as the time from the day of ASCT (day 0) to the day of documented progression/relapse of disease or death. Response pre-ASCT and at day +100 post-ASCT was defined using the response criteria established by the International Myeloma Working Group (IMWG) [16] . OS was calculated from day 0 through the date of death, with censorship at the time of last contact. TRM was defined as death within the first 100 days posttransplantation without evidence of disease progression. Time to neutrophil engraftment was defined as the interval from day 0 until an absolute neutrophil count ≥ 500 cells/mm 3 . Time to platelet engraftment was defined as the interval from day 0 until a platelet count >20,000 cells/mm 3 without the need for transfusion.
Study Design and Statistical Analysis
To ensure that dosage adjustment of melphalan in obese patients did not worsen outcomes, a noninferiority study design for the primary outcome was selected. Before study initiation, a noninferiority margin of 7% in the obese population was considered clinically nonsignificant, assuming a 3-year EFS of 70% in the nonobese population receiving lenalidomide maintenance therapy [17, 18] . Using the noninferiority margin of 7%, a power of 80%, and an α value of .05, a required study sample size of 280 patients was calculated. Continuous nonparametric data were analyzed using the KruskalWallis test, and categorical data with no inherent order and ordered variables were analyzed using Fisher's exact test and Jonckheere's test, respectively. Events occurring over time were compared using Kaplan-Meier methods. The noninferiority of 3-year EFS was assessed using the Z test [19] . A P value <.05 was considered to indicate statistical significance. Statistical analyses were performed using SAS version 9.4 with STAT version 14.1 (SAS Institute, Cary, NC).
RESULTS
A total of 394 patients underwent melphalan ASCT during the study period, 124 of whom were excluded for retransplantation, alternative melphalan regimens, disease states other than multiple myeloma, inability to access chemotherapy orders, and lack of data for assessment. The 270 patients eligible for analysis included 171 (63%) in the obese cohort and 99 (37%) in the nonobese cohort ( Figure 1 ).
Baseline patient characteristics were well matched between the 2 study cohorts ( Table 2 ). The majority of patients were Caucasian (77%), male (56%), and underwent transplantation receiving melphalan dosed at 200 mg/m 2 (94%), at a median age of 61 years. The only detectable differences between the obese and nonobese cohorts were related to weight itself. As expected, the actual and dosing weights, BMI (all P < .001), and dosing BSA (P = .013) were higher in the obese cohort (Table 2) . Following BJH guidelines for transplantation, the obese cohort received melphalan dosed using AdBW in the BSA calculation. For the nonobese cohort, 82 patients (83%) received melphalan dosed using IBW in the BSA calculation, and the remaining 17 patients (17%) received melphalan dosed using ABW in the BSA calculation.
Analysis of high, standard, and unknown risk cytogenetics revealed high-risk cytogenetics in 11% of the obese cohort and 8% of the nonobese cohort and unknown cytogenetic risk in the majority of the total study cohort (P = .75; Table 2 ).
Greater disease severity at diagnosis was noted in the nonobese cohort, with ISS stage III disease in 30%, compared with 18% in the obese cohort; however, this difference was not statistically significantly different (P = .084). Before undergoing transplantation, 71% of the study cohort had received 1 previous line of chemotherapy. Pretransplantation response as assessed by the IMWG response criteria also showed no differences between study cohorts (P = .32), but a greater proportion of the obese cohort compared with the nonobese cohort was in complete response (CR) at the time of transplantation (10% versus 3%). Very good partial response was observed in 26% of the obese cohort and in 35% of the nonobese cohort. Approximately 58% of the study cohort received maintenance therapy post-ASCT, with lenalidomide the most common drug used. Our primary endpoint of 3-year EFS was 41% for the total study cohort. Fewer events occurred in the obese cohort with 51% EFS at 3 years, compared with 40% of the nonobese cohort (P = .0025 for noninferiority). The 95% lower confidence limit established noninferiority (Figure 2 ). Across the study cohort, high-risk cytogenetics, disease severity at diagnosis, and therapy response pre-and post-ASCT were all significantly associated with EFS (Table 3) .
The secondary endpoint of 3-year OS was 59.1% in the obese cohort compared with 63.6% in the nonobese cohort (P = .52). There were no statistically significant differences between the 2 cohorts in terms of IMWG response at day +100 (Table 4) , although 15 patients could not be assessed because of incomplete records. Four patients, including 3 in the obese cohort and 1 in the nonobese cohort, died before evaluation of response at day +100. In the obese cohort, 1 patient died secondary to progressive disease and 2 patients met the criteria for TRM with death from multiorgan failure due to sepsis. TRM secondary to cardiac arrest occurred in 1 patient in the nonobese cohort. The percentage of patients with CR increased in both cohorts at the day +100 assessment, from 10% to 22% in the obese cohort and from 3% to 21% in the nonobese cohort. Very good partial response improved from 26% to 33% in the obese cohort but decreased from 35% to 33% in the nonobese cohort. No statistically significant differences were noted in terms of time to neutrophil or platelet engraftment or hospital LOS (Table 4) .
DISCUSSION
The studies used to evaluate melphalan dosing in the American Society for Blood and Marrow Transplantation guidelines [7] vary in terms of toxicity and efficacy outcomes assessed. The literature on obese dosing of chemotherapy in ASCT shows significant variability in the strategies used to calculate the dosing BSA. The differences noted across the literature include the use of body weights ranging from ABW to IBW, disparity regarding when to use AdBW, AdBW calculations with correction factors ranging from 25% to 40%, and the definition of obesity [8] [9] [10] [11] .
The World Health Organization (WHO) uses BMI for classifying obesity and defines obesity as a BMI ≥30 [20] . Rather than use this WHO BMI-based definition of obesity, however, we chose to use the definition of ≥120% of IBW because of our standard dosing practice at BJH, as well as the lack of a consistent definition for obesity in the literature. Obesity has been defined and evaluated for patient outcomes in various ways, including use of age-adjusted BMI, the WHO BMIbased definitions, and AdBW with differing patient weights in the dosing calculation [8, 9, 11, 20] . These differing definitions hinder interpretation of clinical outcomes in obese patients, who have been found to have an increased risk of nonrelapse mortality [8] and longer LOS [10] , but no differences in EFS, OS, or disease progression compared with nonobese patients [8, 10] . Other studies have reported improvements in OS, EFS, and risk of progression in obese patients [11] . The varying definitions of obesity and dosing weights across studies could be the reason for the differences reported in the literature.
Our primary endpoint of EFS met the noninferiority criterion, with 51% of the obese cohort event-free at 3 years compared with 40% of the nonobese cohort (P = .0025), supporting that the effects of melphalan dosage adjustment do not appear to negatively impact outcomes in obese patients. This finding of noninferiority, which demonstrates that outcomes in obese patients were no worse than their nonobese counterparts despite the melphalan dosage adjustment, differs from reports in the literature linking dosage adjustment to increased risk of disease relapse [21] . Potential reasons for this difference may include that more patients in the nonobese cohort received dose-reduced melphalan at 140 mg/m 2 compared with the obese arm (8.1% versus 4.1%). In addition, based on BJH standard transplantation dosing guidelines, the majority of the nonobese cohort received a lower dose of melphalan with the use of IBW in the BSA calculation. This study was not designed to address the impact of dosage reduction in the nonobese cohort, but future analysis could examine the results of our primary endpoint.
When analyzing the findings of this study, it is important to compare the factors known to impact outcomes of ASCT in multiple myeloma including cytogenetics, disease severity at diagnosis, and response pre-ASCT. High-risk cytogenetics, specifically del(17p), t(14;16), t(14;20), and del(1p), have been associated with risk of disease progression as well as a shortened median OS of 3 years [13] . Only 11% of the obese cohort and 8% of the nonobese cohort had known high-risk cytogenetic abnormalities, whereas highrisk cytogenetics surrounding the immunoglobulin heavy chain (IgH) locus, including t(14;16) and t(14;20), have been reported in up to 40% of patients with multiple myeloma [22] . Although no cytogenetic differences were noted between the obese and nonobese cohorts, it is possible that with further analysis of the patients with unknown cytogenetics, more patients in the nonobese cohort might have been included in the high-risk category, thus affecting the results. After exclusion of patients with unknown risk, the impact of cytogenetics showed a statistically significant difference in EFS, as expected, with a 16-month shorter time to relapse or death in patients with high-risk cytogenetics across the study cohorts (Table 4) .
Staging the severity of myeloma at diagnosis is another important prognostic indicator of clinical outcomes in multiple myeloma. Historically, the DS staging criteria had been used until the ISS was validated in 2005 [15] . Although this 
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Significant P values are in bold type. NE indicates not estimable. * Cytogenetics: High risk, del(17p), t(14;16), t(14;20), del(1p); standard risk, all other cytogenetic abnormalities; unknown risk, no cytogenetic information available. remains in practice, the recently revised ISS criteria were able to further classify severity of disease with the incorporation of cytogenetics and lactate dehydrogenase into the ISS scoring system [23] . Our findings show a nonsignificantly higher percentage of patients with ISS stage III disease in the nonobese cohort compared with the obese cohort (30% versus 18%). The median EFS for the study patients with stage III disease was 24.6 months, similar to the median survival of 29 months in patients with stage III disease reported in the literature [15] . Unfortunately, given the differences between the DS and ISS criteria, the inability to capture consistent patient information to use one staging system and the unknown cytogenetic risk in some patients, it is possible that we were not able to detect a significant difference in baseline staging between the groups, which may have impacted the EFS outcome. The depth of response pretransplantation for patients with multiple myeloma is known to have an impact on the efficacy of ASCT [5, [24] [25] [26] . There were no statistically significant differences between the obese and nonobese cohorts in response pre-ASCT, although a higher percentage of patients in the obese cohort had achieved CR before transplantation (10% versus 3%). Similarly, in terms of response at day +100, there were no statistically significant differences between the 2 cohorts. Consistent with the literature, an improved depth of response was noted in both cohorts [27] .
The finding of no difference in 3-year OS between our 2 study cohorts mirrors recently reported findings of Stadtmauer et al. [28] evaluating EFS and OS in patients undergoing single ASCT plus lenalidomide maintenance; in patients undergoing single ASCT plus 4 cycles of lenalidomide, bortezomib, and dexamethasone consolidation; and in patients undergoing tandem ASCT; however, our survival percentages were lower. We found a 3-year OS of 59.1% in the obese cohort and 63.6% in the nonobese cohort (P = .52), which is lower than the 3-year OS of 83% in the most similar arm of the study, single ASCT plus lenalidomide maintenance. Possible reasons for this difference could include differences in baseline patient characteristics as well as in the induction chemotherapy used.
With our dosage adjustment, our obese patient cohort received a lower dosage of melphalan than the nonobese cohort, as expected. As mentioned above, dosage adjustment for the obese patient population has been used owing to concerns for altered pharmacokinetics in the obese population, leading to increased exposure to chemotherapy from a shift of lipophilic drugs to adipose tissue, reduced liver and renal blood flow, and increased drug binding to expanded plasma protein volume [7, 21] . Grazziutti et al. [9] confirmed this concern, showing an association between higher melphalan dosage and increased mucositis. The melphalan dosage adjustment in obese patients is reasonable, given the low volume of distribution of .5 L/kg, the majority of drug remains confined to the circulation [29] . Given the retrospective nature of our study and the subjective nature of degree of mucositis, as well as diarrhea, we were unable to assess these common adverse effects in our study cohort.
Strengths of this study include the fact that BJH and Siteman Cancer Center at Washington University perform approximately 250 ASCTs per year. The large number of transplantations performed within our relatively short study period gave us the ability to assess clinically important longterm efficacy outcomes in this patient population. BJH's consistent practice of using AdBW for dosage calculations helps eliminate any bias from dosing protocol changes that may sometimes occur with retrospective studies.
This study has several limitations worth noting. Given the standardization of practice at BJH, we did not have the ability to evaluate obese patients who did and did not receive adjusted doses of melphalan. With the retrospective study design, we were unable to collect undocumented data points, including missing patient-specific information on cytogenetics at diagnosis, prognostic scoring, and response pretransplantation, all of which are known to impact clinical outcomes. In addition, given the study's retrospective nature, using a noninferiority design for all study endpoints would have required a prohibitively large series. As BJH is a referral center for ASCT, obtaining complete follow-up data was difficult, which resulted in the censoring of some patients at their last known date alive. Compared with the estimated 70% 3-year EFS for the nonobese patient population, we found a 3-year EFS of 41%. This may be related to demographic differences between our patients and those in the multicenter, international randomized trials used to establish our noninferiority margin [17, 18] . The greatest likely contributing factor, however, is that these trials used a different definition of EFS and followed patients from diagnosis as opposed to the date of ASCT. Finally, although melphalan-specific toxicities, such as mucositis and diarrhea, ideally would be included in this analysis, we were not able to reliably extract these data from the medical records. Nonetheless, theoretically, the use of lower melphalan dosages would not be expected to worsen these toxicities.
In conclusion, this study provides additional insight into clinical outcomes for melphalan ASCT for patients with multiple myeloma between obese and nonobese cohorts with the obese patients receiving dose-adjusted melphalan. Our results establish noninferiority for 3-year EFS in our obese cohort compared with their nonobese counterparts, and suggest that dosage adjustment of melphalan in obese patients does not seem to negatively impact outcomes. Although we agree that this study does not answer the overarching question of the need for dosage adjustment, it does provide some evidence that outcomes are not worse in obese patients receiving adjusted doses. Future studies using consistent and transparent dosing practices are needed to better address the question regarding dosing strategies in melphalan ASCT, with an emphasis on the obese patient population.
